Bardet–Biedl syndrome

Bardet–Biedl syndrome
Domaina, Kashmiri and SUM1 · CC BY-SA 3.0 · source
Name	Bardet–Biedl syndrome
Specialty	Genetics, Ophthalmology, Endocrinology

Bardet–Biedl syndrome is a rare, genetically heterogeneous, multisystem disorder characterized by retinal dystrophy, polydactyly, obesity, renal anomalies, hypogonadism, and cognitive impairment. First characterized in the early 20th century, the condition has been described in clinical reports associated with consanguineous populations and has been the subject of molecular studies involving ciliary proteins and protein trafficking. Clinical management involves coordinated care across pediatric, nephrology, and ophthalmology services and often invokes guidelines from professional bodies.

Signs and symptoms

Affected individuals typically present with progressive visual loss from rod-cone dystrophy, postaxial polydactyly, truncal obesity emerging in childhood, renal dysplasia or cystic disease, hypogonadism with delayed puberty, and cognitive or behavioral differences. Sight loss commonly progresses to legal blindness, prompting evaluations similar to those in patients seen at Moorfields Eye Hospital, Bascom Palmer Eye Institute, Johns Hopkins Hospital, Mayo Clinic, and Massachusetts Eye and Ear. Polydactyly may be managed surgically by teams at institutions such as Great Ormond Street Hospital, Boston Children's Hospital, and Seattle Children's Hospital. Obesity and metabolic sequelae often require interventions recommended by authorities including World Health Organization, American Diabetes Association, European Society of Endocrinology, National Institute for Health and Care Excellence, and American Academy of Pediatrics. Renal manifestations range from structural anomalies to progressive chronic kidney disease, requiring nephrology input analogous to care models at Cleveland Clinic, Mount Sinai Medical Center, and Karolinska University Hospital. Reproductive endocrinology referrals may involve centers like UCLA Health, University College London Hospitals, and Columbia University Irving Medical Center.

Genetics and pathophysiology

The disorder is genetically heterogeneous with pathogenic variants reported in over 20 genes encoding proteins localized to the primary cilium and basal body, implicating defects in intraflagellar transport, ciliogenesis, and protein trafficking. Molecular genetic studies performed at laboratories affiliated with Broad Institute, Wellcome Sanger Institute, National Institutes of Health, Genomics England, and European Molecular Biology Laboratory have identified loci with triallelic inheritance, digenic modifiers, and founder variants in populations studied by teams at University of Alabama at Birmingham, Tel Aviv University, McGill University, University of Cape Town, and University of Lagos. Functional characterization has involved model organisms and systems used by researchers at Harvard Medical School, Stanford University School of Medicine, Max Planck Institute, Cold Spring Harbor Laboratory, and University of California, San Francisco. Cellular pathophysiology links to pathways also researched in contexts such as Alzheimer's disease, Polycystic kidney disease, and ciliopathies studied in consortia including International Rare Diseases Research Consortium and European Reference Networks.

Diagnosis

Diagnosis relies on clinical criteria combining major and minor features, supported by molecular genetic testing using panels, exome sequencing, or genome sequencing available from centers like Invitae, GeneDx, Ambry Genetics, Mayo Clinic Laboratories, and UK Biobank-linked services. Ophthalmological assessment uses techniques performed at tertiary centers such as Bascom Palmer Eye Institute and Scheie Eye Institute, including electroretinography and fundus autofluorescence, while renal imaging and function testing follow protocols practiced at Johns Hopkins Hospital and University of Toronto. Differential diagnosis considers other ciliopathies and syndromes evaluated by multidisciplinary teams at institutions like Children's Hospital of Philadelphia, Royal Children's Hospital Melbourne, and St. Jude Children's Research Hospital. Genetic counseling standards referenced from American College of Medical Genetics and Genomics, European Society of Human Genetics, and National Society of Genetic Counselors guide family testing and carrier screening strategies.

Management and treatment

There is no cure; management is multidisciplinary and symptom-directed, involving ophthalmology for low-vision rehabilitation from providers such as Royal National Institute of Blind People, American Foundation for the Blind, and Helen Keller Services, orthopedic or plastic surgery for limb anomalies at centers like Shriners Hospitals for Children, endocrinology for obesity and metabolic disease with protocols from Endocrine Society and American Diabetes Association, and nephrology for renal replacement therapy consistent with standards from International Society of Nephrology and European Renal Association. Hormone replacement and assisted reproductive techniques may be coordinated with fertility centers including IVF Australia, New Hope Fertility Center, and Boston IVF. Supportive services include special education and behavioral interventions delivered by programs affiliated with UNICEF, UNESCO, and national education authorities. Emerging therapeutic research, including gene therapy, pharmacologic modulation of ciliary function, and precision medicine trials, is being conducted at institutions such as NIH Clinical Center, University of Oxford, University of Cambridge, Massachusetts General Hospital, and biotechnology companies participating in rare disease consortia.

Prognosis and complications

Prognosis varies with the severity of renal disease, rate of retinal degeneration, and metabolic complications; renal failure is a leading cause of morbidity and mortality, managed by dialysis and transplantation services like those at Cleveland Clinic and UCLA Health. Visual impairment affects education and employment outcomes tracked in cohorts from UK Biobank, National Institutes of Health, and longitudinal studies at University of Michigan and University of Sydney. Cardiometabolic complications follow patterns described by American Heart Association and World Heart Federation and require preventive strategies. Lifespan may be shortened primarily by end-stage renal disease and severe infections; coordinated care models from Centers for Disease Control and Prevention, Maternal and Child Health Bureau, and rare disease networks aim to improve long-term outcomes.

Category:Genetic disorders